tanshinone iib
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01452477)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 2 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Unspecified targetINHIBITOR
Bax
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 1,6-dimethylphenanthro(1,2-b)furan-10,11-dione
- tanshinone
- tanshinone
- tanshinone
- tanshinone i
- tanshinone iia
- tanshinone ii a
- tanshinone iib
- tanshinone ii b
- tte-50
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07123701 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2024 | Southern Medical University, Sun Yat-Sen University |
| NCT01452477 | N/A | Oct 1, 2011 | Heilongjiang University of Traditional Chinese Medicine |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Heilongjiang University of Traditional Chinese Medicine | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Southern Medical University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1